Skip to Content

Dichlorphenamide Pregnancy and Breastfeeding Warnings

Dichlorphenamide is also known as: Daranide, Keveyis

Medically reviewed on August 7, 2017

Dichlorphenamide Pregnancy Warnings

This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

US FDA pregnancy category: C

Teratogenic effects (fetal limb reduction defects) were reported following oral administration of this drug in pregnant animals during organogenesis at 350 mg/kg, or 17 times the maximum recommended human dose (200 mg/day) on a body surface area (mg/m2) basis. A no-effect dose has not been established. There are no adequate and well-controlled studies in pregnant women.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Dichlorphenamide Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comment:
-The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Keveyis (dichlorphenamide)." Taro Pharmaceuticals U.S.A. Inc, Hawthorne, NY.

References for breastfeeding information

  1. "Product Information. Keveyis (dichlorphenamide)." Taro Pharmaceuticals U.S.A. Inc, Hawthorne, NY.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide